D
Inotiv, Inc.
NOTV
$2.63
-$0.285-9.79%
D
Sell
12/10/2024Upgraded
Inotiv, Inc. (NOTV) was upgraded to D- from E+ on 12/10/2024 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 83.98% from -$14.81M to -$2.37M, EBIT increased 30.84% from -$18.3M to -$12.65M, and earnings per share increased from -$1.0036 to -$0.7317.
Inotiv, Inc. (NOTV) was upgraded to D- from E+ on 12/10/2024 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 83.98% from -$14.81M to -$2.37M, EBIT increased 30.84% from -$18.3M to -$12.65M, and earnings per share increased from -$1.0036 to -$0.7317.
E
Sell
7/3/2024Downgrade
Inotiv, Inc. (NOTV) was downgraded to E+ from D- on 7/3/2024 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 1.04 to 0.2, and debt to equity increased from 1.54 to 1.89.
Inotiv, Inc. (NOTV) was downgraded to E+ from D- on 7/3/2024 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 1.04 to 0.2, and debt to equity increased from 1.54 to 1.89.
D
Sell
2/2/2024Upgraded
Inotiv, Inc. (NOTV) was upgraded to D- from E+ on 2/2/2024 due to a large increase in the solvency index and volatility index. The quick ratio increased from 0.88 to 0.94.
Inotiv, Inc. (NOTV) was upgraded to D- from E+ on 2/2/2024 due to a large increase in the solvency index and volatility index. The quick ratio increased from 0.88 to 0.94.
E
Sell
11/29/2023Downgrade
Inotiv, Inc. (NOTV) was downgraded to E+ from D- on 11/29/2023 due to a decline in the total return index, volatility index and solvency index.
Inotiv, Inc. (NOTV) was downgraded to E+ from D- on 11/29/2023 due to a decline in the total return index, volatility index and solvency index.
D
Sell
3/14/2023Downgrade
Inotiv, Inc. (NOTV) was downgraded to D- from D on 3/14/2023 due to a major decline in the solvency index, total return index and volatility index. Debt to equity increased from 1 to 1.36, and the quick ratio declined from 0.72 to 0.71.
Inotiv, Inc. (NOTV) was downgraded to D- from D on 3/14/2023 due to a major decline in the solvency index, total return index and volatility index. Debt to equity increased from 1 to 1.36, and the quick ratio declined from 0.72 to 0.71.
D
Sell
6/1/2022Downgrade
Inotiv, Inc. (NOTV) was downgraded to D from D+ on 6/1/2022 due to a decline in the total return index and volatility index.
Inotiv, Inc. (NOTV) was downgraded to D from D+ on 6/1/2022 due to a decline in the total return index and volatility index.
D
Sell
5/16/2022Upgraded
Inotiv, Inc. (NOTV) was upgraded to D+ from D- on 5/16/2022 due to an increase in the total return index.
Inotiv, Inc. (NOTV) was upgraded to D+ from D- on 5/16/2022 due to an increase in the total return index.
D
Sell
5/13/2022Downgrade
Inotiv, Inc. (NOTV) was downgraded to D- from D+ on 5/13/2022 due to a decline in the total return index and volatility index.
Inotiv, Inc. (NOTV) was downgraded to D- from D+ on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/4/2022Upgraded
Inotiv, Inc. (NOTV) was upgraded to D+ from D- on 05/04/2022.
Inotiv, Inc. (NOTV) was upgraded to D+ from D- on 05/04/2022.
D
Sell
5/1/2022Downgrade
Inotiv, Inc. (NOTV) was downgraded to D- from D+ on 5/1/2022 due to a decline in the volatility index and total return index.
Inotiv, Inc. (NOTV) was downgraded to D- from D+ on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/21/2022Upgraded
Inotiv, Inc. (NOTV) was upgraded to D+ from D- on 04/21/2022.
Inotiv, Inc. (NOTV) was upgraded to D+ from D- on 04/21/2022.
D
Sell
4/20/2022Downgrade
Inotiv, Inc. (NOTV) was downgraded to D- from D+ on 4/20/2022 due to a significant decline in the efficiency index, growth index and total return index. Earnings per share declined from $0.0619 to -$3.9314, net income declined 985.17% from $9.38M to -$83.05M, and operating cash flow declined 142.38% from $2.7M to -$1.14M.
Inotiv, Inc. (NOTV) was downgraded to D- from D+ on 4/20/2022 due to a significant decline in the efficiency index, growth index and total return index. Earnings per share declined from $0.0619 to -$3.9314, net income declined 985.17% from $9.38M to -$83.05M, and operating cash flow declined 142.38% from $2.7M to -$1.14M.
D
Sell
2/16/2022Downgrade
Inotiv, Inc. (NOTV) was downgraded to D+ from C- on 2/16/2022 due to a noticeable decline in the total return index, volatility index and solvency index.
Inotiv, Inc. (NOTV) was downgraded to D+ from C- on 2/16/2022 due to a noticeable decline in the total return index, volatility index and solvency index.
C
Hold
1/7/2022Downgrade
Inotiv, Inc. (NOTV) was downgraded to C- from C on 1/7/2022 due to a significant decline in the total return index.
Inotiv, Inc. (NOTV) was downgraded to C- from C on 1/7/2022 due to a significant decline in the total return index.
C
Hold
12/23/2021Upgraded
Inotiv, Inc. (NOTV) was upgraded to C from D+ on 12/23/2021 due to a significant increase in the efficiency index, solvency index and growth index. Net income increased 729.09% from -$2.27M to $14.25M, earnings per share increased from -$0.1545 to $0.3574, and the quick ratio increased from 0.95 to 3.04.
Inotiv, Inc. (NOTV) was upgraded to C from D+ on 12/23/2021 due to a significant increase in the efficiency index, solvency index and growth index. Net income increased 729.09% from -$2.27M to $14.25M, earnings per share increased from -$0.1545 to $0.3574, and the quick ratio increased from 0.95 to 3.04.
D
Sell
11/9/2021Upgraded
Inotiv, Inc. (NOTV) was upgraded to D+ from D- on 11/09/2021.
Inotiv, Inc. (NOTV) was upgraded to D+ from D- on 11/09/2021.
D
Sell
11/8/2021Downgrade
Inotiv, Inc. (NOTV) was downgraded to D- from D+ on 11/8/2021 due to a decline in the growth index. Earnings per share declined from -$0.0648 to -$0.1545, and EBIT declined 54.32% from -$521 to -$804.
Inotiv, Inc. (NOTV) was downgraded to D- from D+ on 11/8/2021 due to a decline in the growth index. Earnings per share declined from -$0.0648 to -$0.1545, and EBIT declined 54.32% from -$521 to -$804.
D
Sell
8/2/2021Upgraded
Inotiv, Inc. (NOTV) was upgraded to D+ from D on 8/2/2021 due to an increase in the volatility index.
Inotiv, Inc. (NOTV) was upgraded to D+ from D on 8/2/2021 due to an increase in the volatility index.
D
Sell
5/21/2021Downgrade
Inotiv, Inc. (NOTV) was downgraded to D from D+ on 5/21/2021 due to a decline in the growth index, total return index and volatility index. EBIT declined 3,821.43% from $14 to -$521, and earnings per share declined from -$0.0332 to -$0.0648.
Inotiv, Inc. (NOTV) was downgraded to D from D+ on 5/21/2021 due to a decline in the growth index, total return index and volatility index. EBIT declined 3,821.43% from $14 to -$521, and earnings per share declined from -$0.0332 to -$0.0648.
D
Sell
5/6/2021Upgraded
Inotiv, Inc. (NOTV) was upgraded to D+ from D on 5/6/2021 due to a significant increase in the total return index, volatility index and growth index. Operating cash flow increased 1,820.83% from -$96 to $1.65M, EBIT increased 101.1% from -$1.27M to $14, and earnings per share increased from -$0.1633 to -$0.0332.
Inotiv, Inc. (NOTV) was upgraded to D+ from D on 5/6/2021 due to a significant increase in the total return index, volatility index and growth index. Operating cash flow increased 1,820.83% from -$96 to $1.65M, EBIT increased 101.1% from -$1.27M to $14, and earnings per share increased from -$0.1633 to -$0.0332.
D
Sell
5/1/2020Downgrade
Bioanalytical Systems, Inc. (BASI) was downgraded to D from D+ on 5/1/2020 due to a substantial decline in the efficiency index, total return index and solvency index.
Bioanalytical Systems, Inc. (BASI) was downgraded to D from D+ on 5/1/2020 due to a substantial decline in the efficiency index, total return index and solvency index.
D
Sell
4/8/2020Downgrade
Bioanalytical Systems, Inc. (BASI) was downgraded to D+ from C- on 4/8/2020 due to a substantial decline in the total return index and volatility index.
Bioanalytical Systems, Inc. (BASI) was downgraded to D+ from C- on 4/8/2020 due to a substantial decline in the total return index and volatility index.
C
Hold
2/18/2020Downgrade
Bioanalytical Systems, Inc. (BASI) was downgraded to C- from C on 2/18/2020 due to a noticeable decline in the growth index, total return index and efficiency index. Earnings per share declined from $0.0191 to -$0.1337, net income declined 591.72% from $290 to -$1.43M, and EBIT declined 208.17% from $943 to -$1.02M.
Bioanalytical Systems, Inc. (BASI) was downgraded to C- from C on 2/18/2020 due to a noticeable decline in the growth index, total return index and efficiency index. Earnings per share declined from $0.0191 to -$0.1337, net income declined 591.72% from $290 to -$1.43M, and EBIT declined 208.17% from $943 to -$1.02M.
C
Hold
12/27/2019Upgraded
Bioanalytical Systems, Inc. (BASI) was upgraded to C from C- on 12/27/2019 due to a substantial increase in the total return index, growth index and efficiency index. EBIT increased 477.2% from -$250 to $943, net income increased 168.08% from -$426 to $290, and earnings per share increased from -$0.0406 to $0.0191.
Bioanalytical Systems, Inc. (BASI) was upgraded to C from C- on 12/27/2019 due to a substantial increase in the total return index, growth index and efficiency index. EBIT increased 477.2% from -$250 to $943, net income increased 168.08% from -$426 to $290, and earnings per share increased from -$0.0406 to $0.0191.
C
Hold
5/15/2019Upgraded
Bioanalytical Systems, Inc. (BASI) was upgraded to C- from D+ on 5/15/2019 due to a substantial increase in the total return index and volatility index.
Bioanalytical Systems, Inc. (BASI) was upgraded to C- from D+ on 5/15/2019 due to a substantial increase in the total return index and volatility index.
D
Sell
3/12/2019Upgraded
Bioanalytical Systems, Inc. (BASI) was upgraded to D+ from D on 3/12/2019 due to an increase in the growth index, total return index and efficiency index. Net income increased 57.5% from -$200 to -$85, and earnings per share increased from -$0.0196 to -$0.01.
Bioanalytical Systems, Inc. (BASI) was upgraded to D+ from D on 3/12/2019 due to an increase in the growth index, total return index and efficiency index. Net income increased 57.5% from -$200 to -$85, and earnings per share increased from -$0.0196 to -$0.01.
D
Sell
12/21/2018Downgrade
Bioanalytical Systems, Inc. (BASI) was downgraded to D from D+ on 12/21/2018 due to a decline in the valuation index, efficiency index and total return index. Net income declined 166.67% from -$75 to -$200.
Bioanalytical Systems, Inc. (BASI) was downgraded to D from D+ on 12/21/2018 due to a decline in the valuation index, efficiency index and total return index. Net income declined 166.67% from -$75 to -$200.
D
Sell
8/16/2018Downgrade
Bioanalytical Systems, Inc. (BASI) was downgraded to D+ from C- on 8/16/2018 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 236.36% from $55 to -$75, and total capital declined 1.01% from $13.03M to $12.9M.
Bioanalytical Systems, Inc. (BASI) was downgraded to D+ from C- on 8/16/2018 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 236.36% from $55 to -$75, and total capital declined 1.01% from $13.03M to $12.9M.
C
Hold
5/10/2018Upgraded
Bioanalytical Systems, Inc. (BASI) was upgraded to C- from D+ on 5/10/2018 due to an increase in the volatility index.
Bioanalytical Systems, Inc. (BASI) was upgraded to C- from D+ on 5/10/2018 due to an increase in the volatility index.
D
Sell
4/6/2018Downgrade
Bioanalytical Systems, Inc. (BASI) was downgraded to D+ from C- on 4/6/2018 due to a decline in the volatility index, total return index and efficiency index. Net income declined 88.65% from $229 to $26, and total capital declined 0.17% from $13.05M to $13.02M.
Bioanalytical Systems, Inc. (BASI) was downgraded to D+ from C- on 4/6/2018 due to a decline in the volatility index, total return index and efficiency index. Net income declined 88.65% from $229 to $26, and total capital declined 0.17% from $13.05M to $13.02M.
C
Hold
1/29/2018Downgrade
Bioanalytical Systems, Inc. (BASI) was downgraded to C- from C on 1/29/2018 due to a large decline in the total return index.
Bioanalytical Systems, Inc. (BASI) was downgraded to C- from C on 1/29/2018 due to a large decline in the total return index.
C
Hold
12/22/2017Upgraded
Bioanalytical Systems, Inc. (BASI) was upgraded to C from C- on 12/22/2017 due to a substantial increase in the valuation index, efficiency index and total return index. Net income increased 3.62% from $221 to $229.
Bioanalytical Systems, Inc. (BASI) was upgraded to C from C- on 12/22/2017 due to a substantial increase in the valuation index, efficiency index and total return index. Net income increased 3.62% from $221 to $229.
C
Hold
12/7/2017Upgraded
Bioanalytical Systems, Inc. (BASI) was upgraded to C- from D+ on 12/7/2017 due to a large increase in the total return index, growth index and volatility index. Operating cash flow increased 253.79% from -$448 to $689.
Bioanalytical Systems, Inc. (BASI) was upgraded to C- from D+ on 12/7/2017 due to a large increase in the total return index, growth index and volatility index. Operating cash flow increased 253.79% from -$448 to $689.
D
Sell
6/2/2017Upgraded
Bioanalytical Systems, Inc. (BASI) was upgraded to D+ from D on 6/2/2017 due to a significant increase in the total return index, volatility index and growth index. Earnings per share increased from $0.002 to $0.05, EBIT increased 490.43% from $94 to $555, and total revenue increased 3% from $6.17M to $6.36M.
Bioanalytical Systems, Inc. (BASI) was upgraded to D+ from D on 6/2/2017 due to a significant increase in the total return index, volatility index and growth index. Earnings per share increased from $0.002 to $0.05, EBIT increased 490.43% from $94 to $555, and total revenue increased 3% from $6.17M to $6.36M.
D
Sell
2/14/2017Upgraded
Bioanalytical Systems, Inc. (BASI) was upgraded to D from D- on 2/14/2017 due to an increase in the volatility index and total return index.
Bioanalytical Systems, Inc. (BASI) was upgraded to D from D- on 2/14/2017 due to an increase in the volatility index and total return index.
D
Sell
1/25/2017Downgrade
Bioanalytical Systems, Inc. (BASI) was downgraded to D- from D on 1/25/2017 due to a large decline in the efficiency index, growth index and total return index. Net income declined 370.44% from -$433 to -$2.04M, earnings per share declined from -$0.0534 to -$0.2512, and EBIT declined 150.14% from -$365 to -$913.
Bioanalytical Systems, Inc. (BASI) was downgraded to D- from D on 1/25/2017 due to a large decline in the efficiency index, growth index and total return index. Net income declined 370.44% from -$433 to -$2.04M, earnings per share declined from -$0.0534 to -$0.2512, and EBIT declined 150.14% from -$365 to -$913.
D
Sell
3/11/2016Downgrade
Bioanalytical Systems Inc. (BASI) was downgraded to D from C- on 3/11/2016 due to a major decline in the volatility index and total return index.
Bioanalytical Systems Inc. (BASI) was downgraded to D from C- on 3/11/2016 due to a major decline in the volatility index and total return index.
C
Hold
2/18/2016Downgrade
Bioanalytical Systems Inc. (BASI) was downgraded to C- from C on 2/18/2016 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 28.83% from -$711 to -$506, and total capital declined 0.74% from $15.61M to $15.5M.
Bioanalytical Systems Inc. (BASI) was downgraded to C- from C on 2/18/2016 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 28.83% from -$711 to -$506, and total capital declined 0.74% from $15.61M to $15.5M.
C
Hold
12/28/2015Downgrade
Bioanalytical Systems Inc. (BASI) was downgraded to C from C+ on 12/28/2015 due to a significant decline in the growth index, valuation index and total return index. EBIT declined 186.87% from $914 to -$794, earnings per share declined from $0.1638 to -$0.1043, and total revenue declined 19.07% from $6.15M to $4.98M.
Bioanalytical Systems Inc. (BASI) was downgraded to C from C+ on 12/28/2015 due to a significant decline in the growth index, valuation index and total return index. EBIT declined 186.87% from $914 to -$794, earnings per share declined from $0.1638 to -$0.1043, and total revenue declined 19.07% from $6.15M to $4.98M.
C
Hold
8/14/2015Upgraded
Bioanalytical Systems Inc. (BASI) was upgraded to C+ from D+ on 8/14/2015 due to a significant increase in the valuation index, growth index and efficiency index. EBIT increased 3,164.29% from $28 to $914, net income increased 885.33% from $150 to $1.48M, and operating cash flow increased 22.3% from $601 to $735.
Bioanalytical Systems Inc. (BASI) was upgraded to C+ from D+ on 8/14/2015 due to a significant increase in the valuation index, growth index and efficiency index. EBIT increased 3,164.29% from $28 to $914, net income increased 885.33% from $150 to $1.48M, and operating cash flow increased 22.3% from $601 to $735.
D
Sell
7/28/2015Downgrade
Bioanalytical Systems Inc. (BASI) was downgraded to D+ from C- on 7/28/2015 due to a major decline in the volatility index.
Bioanalytical Systems Inc. (BASI) was downgraded to D+ from C- on 7/28/2015 due to a major decline in the volatility index.
C
Hold
5/21/2015Upgraded
Bioanalytical Systems Inc. (BASI) was upgraded to C- from D+ on 5/21/2015 due to an increase in the growth index, efficiency index and solvency index. Debt to equity declined from 0.68 to 0.59, and the quick ratio increased from 0.48 to 0.49.
Bioanalytical Systems Inc. (BASI) was upgraded to C- from D+ on 5/21/2015 due to an increase in the growth index, efficiency index and solvency index. Debt to equity declined from 0.68 to 0.59, and the quick ratio increased from 0.48 to 0.49.
D
Sell
2/19/2015Downgrade
Bioanalytical Systems Inc. (BASI) was downgraded to D+ from C- on 2/19/2015 due to a decline in the growth index, total return index and valuation index. EBIT declined 223.48% from -$115 to $142, operating cash flow declined 134.33% from $469 to -$161, and earnings per share declined from -$0.05 to $0.0065.
Bioanalytical Systems Inc. (BASI) was downgraded to D+ from C- on 2/19/2015 due to a decline in the growth index, total return index and valuation index. EBIT declined 223.48% from -$115 to $142, operating cash flow declined 134.33% from $469 to -$161, and earnings per share declined from -$0.05 to $0.0065.
C
Hold
1/14/2015Downgrade
Bioanalytical Systems Inc. (BASI) was downgraded to C- from C on 1/14/2015 due to a large decline in the growth index, efficiency index and solvency index. Earnings per share declined from $0.0155 to -$0.05, net income declined 287.91% from $215 to -$404, and EBIT declined 144.92% from $256 to -$115.
Bioanalytical Systems Inc. (BASI) was downgraded to C- from C on 1/14/2015 due to a large decline in the growth index, efficiency index and solvency index. Earnings per share declined from $0.0155 to -$0.05, net income declined 287.91% from $215 to -$404, and EBIT declined 144.92% from $256 to -$115.
C
Hold
12/24/2014Upgraded
Bioanalytical Systems Inc. (BASI) was upgraded to C from C- on 12/24/2014 due to a noticeable increase in the growth index, solvency index and valuation index. EBIT increased 143.81% from $105 to $256, the quick ratio increased from 0.3 to 0.47, and total revenue increased 2.03% from $5.91M to $6.03M.
Bioanalytical Systems Inc. (BASI) was upgraded to C from C- on 12/24/2014 due to a noticeable increase in the growth index, solvency index and valuation index. EBIT increased 143.81% from $105 to $256, the quick ratio increased from 0.3 to 0.47, and total revenue increased 2.03% from $5.91M to $6.03M.
C
Hold
3/7/2014Downgrade
Bioanalytical Systems Inc. (BASI) was downgraded to C- from C on 3/7/2014 due to a decline in the total return index and volatility index.
Bioanalytical Systems Inc. (BASI) was downgraded to C- from C on 3/7/2014 due to a decline in the total return index and volatility index.
NASDAQ
03/13/2025 4:00PM Eastern
Quotes delayed
